Antibiotics Market to Reach $75.2 Billion by 2035

Antibiotics market was valued at $52.9 billion in 2025 and is anticipated to reach $75.2 billion by 2035, expanding at a CAGR of 3.7% from 2026 to 2035. Market growth is primarily driven by the sustained prevalence of infectious diseases and the rising threat of antimicrobial resistance (AMR), which continues to challenge global healthcare systems. According to the World Health Organization, lower respiratory infections remain among the leading causes of mortality worldwide, thereby maintaining consistent demand for antibiotic treatments across both hospital and outpatient settings. Furthermore, estimates from the Organisation for Economic Co-operation and Development suggest that antimicrobial resistance could result in approximately 2.4 million deaths across Europe, North America, and Australia by 2050, emphasizing the urgent need for effective and innovative antibiotic therapies. In addition, the growing number of hospital admissions and surgical procedures is contributing to increased antibiotic consumption, particularly in intensive care and post-operative care settings. Among drug classes, beta-lactams continue to dominate the market due to their broad-spectrum efficacy, safety profile, and cost-effectiveness, while respiratory tract infections represent the largest application segment globally.

Browse the full report description of “Antibiotics Market Size, Share & Trends Analysis Report by Drug Type (Beta-lactams, Macrolides, Fluoroquinolones, Tetracyclines, Aminoglycosides, Sulfonamides, Glycopeptides, Oxazolidinones, Lincosamides, Others), by Application (Respiratory Tract Infections, Urinary Tract Infections, Skin & Soft Tissue Infections, Gastrointestinal Infections, Sepsis & Bloodstream Infections), and Forecast Period (2026–2035)” at https://www.omrglobal.com/industry-reports/antibiotics-market

Powering the Fight Against Infections: Leaders Driving Innovation in the Antibiotics Market

The key players in the antibiotics market include Pfizer Inc., GlaxoSmithKline plc, Merck & Co., Inc., Novartis AG, and Sanofi S.A., among others. These companies are driving innovation in antibiotic therapies through the development of broad-spectrum and targeted treatments, advancements in antimicrobial resistance (AMR) solutions, and improved drug formulations. Their focus on enhancing efficacy, safety, and resistance management is supporting the growing need for effective infection control and global public health outcomes.

• In April 2025, Merck & Co., Inc. began construction of a $ 1 billion biologics manufacturing facility in Wilmington, Delaware. The investment aims to strengthen domestic production capacity and support growing demand for advanced biologic therapies. This facility will enhance supply chain resilience and reinforce the company’s long-term manufacturing capabilities in the U.S.
• In March 2024, Pfizer Inc. received a positive opinion from the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency for EMBLAVEO. This novel antibiotic targets multidrug-resistant Gram-negative infections, addressing a critical need in antimicrobial resistance (AMR). The approval highlights progress in developing advanced therapies to combat resistant pathogens.

Market Coverage

• The market number available for – 2025-2035
• Base year- 2025
• Forecast period- 2026-2035
• Segment Covered-
  • By Drug Type
  • By Application
• Regions Covered-
  • North America
  • Europe
  • Asia-Pacific
  • Rest of the World
• Competitive Landscape - Pfizer Inc., GlaxoSmithKline plc, Merck & Co., Inc., Novartis AG, and Sanofi S.A., among others.

Key questions addressed by the report.

• What is the market growth rate?
• Which segment and region dominate the market in the base year?
• Which segment and region will project the fastest growth in the market?
• Who is the leader in the market?
• How are players addressing challenges to sustain growth?
• Where is the investment opportunity?

Global Antibiotics Market Report Segment

By Drug Type

• Beta-lactams
• Macrolides
• Fluoroquinolones
• Tetracyclines
• Aminoglycosides
• Sulfonamides
• Glycopeptides
• Oxazolidinones
• Lincosamides
• Others

By Application

• Respiratory tract infections
• Urinary tract infections (UTIs)
• Skin & soft tissue infections
• Gastrointestinal infections
• Sepsis & bloodstream infections

Global Antibiotics Market Report Segment by Region

North America

• United States
• Canada

Europe

• UK
• Germany
• Italy
• Spain
• France
• Russia
• Rest of Europe

Asia-Pacific

• China
• India
• Japan
• South Korea
• Australia and New Zealand
• ASEAN Economies
• Rest of Asia-Pacific

Rest of the World

• Latin America
• Middle East & Africa

To learn more about this report request a sample copy @ https://www.omrglobal.com/request-sample/antibiotics-market